Global and United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report & Forecast 2024-2031

Report ID: 1838651 | Published Date: Jan 2025 | No. of Page: 104 | Base Year: 2024 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million) Introduction
    1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Outlook 2017 VS 2022 VS 2028
        1.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size for the Year 2017-2028
        1.2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size for the Year 2017-2028
    1.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States B-Cell Maturation Antigen (BCMA) Targeted Therapies in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Dynamics
        1.4.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Trends
        1.4.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
        1.4.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges
        1.4.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
    1.5 Study Objectives
    1.6 Years Considered
2 B-Cell Maturation Antigen (BCMA) Targeted Therapies by Type
    2.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segment by Type
        2.1.1 Bispecific Antibodies
        2.1.2 Antibody Drug Conjugates
        2.1.3 Chimeric Antigen Receptor T-Cells
    2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2017, 2022 & 2028)
    2.3 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2017-2028)
    2.4 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2017, 2022 & 2028)
    2.5 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2017-2028)
3 B-Cell Maturation Antigen (BCMA) Targeted Therapies by Application
    3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Segment by Application
        3.1.1 Liver Cancer
        3.1.2 Respiratory Cancer
        3.1.3 Brain Cancer
        3.1.4 Others
    3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2017, 2022 & 2028)
    3.3 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2017-2028)
    3.4 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2017, 2022 & 2028)
    3.5 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2017-2028)
4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Competitor Landscape by Company
    4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Company
        4.1.1 Top Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies Ranked by Revenue (2021)
        4.1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Player (2017-2022)
    4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Concentration Ratio (CR)
        4.2.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of B-Cell Maturation Antigen (BCMA) Targeted Therapies in 2021
        4.2.3 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Headquarters, Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million) Type
        4.3.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Headquarters and Area Served
        4.3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Company
        4.5.1 Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players in United States, Ranked by Revenue (2021)
        4.5.2 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Players (2020, 2021 & 2022)
5 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region
    5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2017-2028)
        5.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2017-2022
        5.2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth 2017-2028
        6.1.2 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth 2017-2028
        6.3.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth 2017-2028
        6.4.2 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 U.A.E
7 Company Profiles
    7.1 Transposagen Biopharmaceuticals
        7.1.1 Transposagen Biopharmaceuticals Company Details
        7.1.2 Transposagen Biopharmaceuticals Business Overview
        7.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.1.4 Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.1.5 Transposagen Biopharmaceuticals Recent Development
    7.2 Sutro Biopharma
        7.2.1 Sutro Biopharma Company Details
        7.2.2 Sutro Biopharma Business Overview
        7.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.2.4 Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.2.5 Sutro Biopharma Recent Development
    7.3 Malin Corporation
        7.3.1 Malin Corporation Company Details
        7.3.2 Malin Corporation Business Overview
        7.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.3.4 Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.3.5 Malin Corporation Recent Development
    7.4 Eureka Therapeutics
        7.4.1 Eureka Therapeutics Company Details
        7.4.2 Eureka Therapeutics Business Overview
        7.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.4.4 Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.4.5 Eureka Therapeutics Recent Development
    7.5 firstVentury Equity
        7.5.1 firstVentury Equity Company Details
        7.5.2 firstVentury Equity Business Overview
        7.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.5.4 firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.5.5 firstVentury Equity Recent Development
    7.6 Five Prime Therapeutics
        7.6.1 Five Prime Therapeutics Company Details
        7.6.2 Five Prime Therapeutics Business Overview
        7.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.6.4 Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.6.5 Five Prime Therapeutics Recent Development
    7.7 Credit Suisse Securities
        7.7.1 Credit Suisse Securities Company Details
        7.7.2 Credit Suisse Securities Business Overview
        7.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.7.4 Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.7.5 Credit Suisse Securities Recent Development
    7.8 Dana-Farber Cancer Institute
        7.8.1 Dana-Farber Cancer Institute Company Details
        7.8.2 Dana-Farber Cancer Institute Business Overview
        7.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.8.4 Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.8.5 Dana-Farber Cancer Institute Recent Development
    7.9 Deerfield Partners
        7.9.1 Deerfield Partners Company Details
        7.9.2 Deerfield Partners Business Overview
        7.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.9.4 Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.9.5 Deerfield Partners Recent Development
    7.10 Onyx Pharmaceuticals
        7.10.1 Onyx Pharmaceuticals Company Details
        7.10.2 Onyx Pharmaceuticals Business Overview
        7.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.10.4 Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.10.5 Onyx Pharmaceuticals Recent Development
    7.11 Juno Therapeutics
        7.11.1 Juno Therapeutics Company Details
        7.11.2 Juno Therapeutics Business Overview
        7.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
        7.11.4 Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
        7.11.5 Juno Therapeutics Recent Development
8 Research Findings and Conclusion
9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends
    Table 3. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
    Table 4. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges
    Table 5. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
    Table 6. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Player, 2017-2022
    Table 13. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies as of 2021)
    Table 15. Top Players of B-Cell Maturation Antigen (BCMA) Targeted Therapies in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Transposagen Biopharmaceuticals Company Details
    Table 31. Transposagen Biopharmaceuticals Business Overview
    Table 32. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 33. Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 34. Transposagen Biopharmaceuticals Recent Development
    Table 35. Sutro Biopharma Company Details
    Table 36. Sutro Biopharma Business Overview
    Table 37. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 38. Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 39. Sutro Biopharma Recent Development
    Table 40. Malin Corporation Company Details
    Table 41. Malin Corporation Business Overview
    Table 42. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 43. Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 44. Malin Corporation Recent Development
    Table 45. Eureka Therapeutics Company Details
    Table 46. Eureka Therapeutics Business Overview
    Table 47. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 48. Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 49. Eureka Therapeutics Recent Development
    Table 50. firstVentury Equity Company Details
    Table 51. firstVentury Equity Business Overview
    Table 52. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 53. firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 54. firstVentury Equity Recent Development
    Table 55. Five Prime Therapeutics Company Details
    Table 56. Five Prime Therapeutics Business Overview
    Table 57. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 58. Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 59. Five Prime Therapeutics Recent Development
    Table 60. Credit Suisse Securities Company Details
    Table 61. Credit Suisse Securities Business Overview
    Table 62. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 63. Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 64. Credit Suisse Securities Recent Development
    Table 65. Dana-Farber Cancer Institute Company Details
    Table 66. Dana-Farber Cancer Institute Business Overview
    Table 67. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 68. Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 69. Dana-Farber Cancer Institute Recent Development
    Table 70. Deerfield Partners Company Details
    Table 71. Deerfield Partners Business Overview
    Table 72. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 73. Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 74. Deerfield Partners Recent Development
    Table 75. Onyx Pharmaceuticals Company Details
    Table 76. Onyx Pharmaceuticals Business Overview
    Table 77. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 78. Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 79. Onyx Pharmaceuticals Recent Development
    Table 80. Juno Therapeutics Company Details
    Table 81. Juno Therapeutics Business Overview
    Table 82. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product
    Table 83. Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022) & (US$ Million)
    Table 84. Juno Therapeutics Recent Development
    Table 85. Research Programs/Design for This Report
    Table 86. Key Data Information from Secondary Sources
    Table 87. Key Data Information from Primary Sources
List of Figures
    Figure 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Picture
    Figure 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2017-2028 (US$ Million)
    Figure 4. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size 2017-2028 (US$ Million)
    Figure 6. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share in Global 2017-2028
    Figure 7. B-Cell Maturation Antigen (BCMA) Targeted Therapies Report Years Considered
    Figure 8. Product Picture of Bispecific Antibodies
    Figure 9. Product Picture of Antibody Drug Conjugates
    Figure 10. Product Picture of Chimeric Antigen Receptor T-Cells
    Figure 11. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Type in 2022 & 2028
    Figure 12. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2017-2028) & (US$ Million)
    Figure 13. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Type (2017-2028)
    Figure 14. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Type in 2022 & 2028
    Figure 15. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type (2017-2028) & (US$ Million)
    Figure 16. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Type (2017-2028)
    Figure 17. Product Picture of Liver Cancer
    Figure 18. Product Picture of Respiratory Cancer
    Figure 19. Product Picture of Brain Cancer
    Figure 20. Product Picture of Others
    Figure 21. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Application in 2022 & 2028
    Figure 22. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2017-2028) & (US$ Million)
    Figure 23. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Application (2017-2028)
    Figure 24. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Application in 2022 & 2028
    Figure 25. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application (2017-2028) & (US$ Million)
    Figure 26. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Application (2017-2028)
    Figure 27. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 28. U.S. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 31. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. U.K. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 37. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Taiwan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Indonesia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Thailand B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Malaysia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Philippines B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 48. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 52. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. U.A.E B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Transposagen Biopharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 56. Sutro Biopharma Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 57. Malin Corporation Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 58. Eureka Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 59. firstVentury Equity Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 60. Five Prime Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 61. Credit Suisse Securities Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 62. Dana-Farber Cancer Institute Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 63. Deerfield Partners Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 64. Onyx Pharmaceuticals Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 65. Juno Therapeutics Revenue Growth Rate in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2017-2022)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Frequently Asked Questions
B-Cell Maturation Antigen (BCMA) Targeted Therapies report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
B-Cell Maturation Antigen (BCMA) Targeted Therapies report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
B-Cell Maturation Antigen (BCMA) Targeted Therapies report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports